Study Finds That Consumers Prefer Regenica® Overnight Repair To SkinMedica TNS Essential Serum®

Independent Company Research Reveals Skincare Product Preferences in Blinded, Split-face Study

Feb 25, 2014, 08:00 ET from Suneva Medical, Inc.

SAN DIEGO, CA, Feb. 25, 2014 /PRNewswire/ -- Suneva Medical, Inc., a privately-held aesthetics company, today announced the results of a third-party study which examined consumer preferences of Regenica® Overnight Repair (Regenica®) relative to SkinMedica's TNS Essential Serum® (TNS®). The blinded, split-face study, conducted by global independent science safety company, UL, revealed that nearly twice as many users preferred Regenica® overall. The study, which included women between the ages of 35 and 60, determined that 79% of consumers preferred the smell of Regenica® to TNS® and they reported increased radiance, smoother texture, and a more even and rejuvenated skin tone. Additionally, 76% of study participants reported that they would recommend Regenica® to a friend.

"TNS® brought growth factors into the mainstream a decade ago," commented Nicholas L. Teti, Jr., Chairman and Chief Executive Officer of Suneva Medical. "Regenica® represents the latest in growth factor technology. The study clearly evaluates the key attributes consumers look for in skincare products and we are pleased that Regenica® excelled."  

The Regenica® skincare line is distributed by Suneva Medical. Suneva Medical also has a co-promotion agreement with Obagi Medical Products, Inc. to distribute Regenica® in the U.S. The product line is exclusively dispensed through physician offices and is available for purchase in dermatology, plastic surgery and other physician practices.

To learn more about Regenica®, visit, or follow on Facebook:, Twitter @RegenicaSkin and Instagram: RegenicaSkincare.

About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill® in the US, Korea and Singapore; ReFissa® and Regenica® in the U.S. and Bellafill® in Canada. For more information, visit

TNS® and TNS Essential Serum® are registered trademarks of Allergan, Inc.

Regenica® is manufactured under U.S. Patent No. 8,524,494.

SOURCE Suneva Medical, Inc.